The study of Pharmacodynamics focuses on how medications affect the body. The drug's interaction with tissue receptors found within cell membranes or intracellular fluid is the most frequent method. The amount of the activating medication (the "agonist") affects the degree of receptor activation and the ensuing biological reaction. The dose-response curve, which charts the medication dose (or concentration) against its effect, provides an explanation for this relationship. Patient characteristics (such as age and illness) and the availability of additional medications that compete with it for binding at the same receptor (such as receptor "antagonists") might have an impact on this crucial pharmacodynamic interaction. Some medications that operate on the same receptor (or tissue) differ in their ability to produce large biological reactions (i.e., their "efficacy") and the dosage needed to produce such responses (i.e., their "potency"). Drug receptors can be categorised according to how selectively they react to various medicines. Drugs can occasionally cause a diminished reaction when receptors or bodily systems are exposed to them repeatedly
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia